Liza Villaruz
机构: Assistant Professor, University of Pittburgh
每年引用次数
引用次数
引用: 6,452
H-指数: 31
I10-指数 : 56
出版物: 150
Do oncogenic drivers exist in squamous cell carcinoma of the lung
Mark A. Socinski , Timothy F. Burns , Liza C. Villaruz
Oncology 27 ( 9) 906
4
2013
Immunotherapy in lung cancer
Hassane Zarour , Mark A. Socinski , Aparna Kalyan , Liza C. Villaruz
Translational lung cancer research 3 ( 1) 2 -14
32
2014
Lung Cancer Survival Prediction Using Instance-Specific Bayesian Networks.
Gregory F. Cooper , Fattaneh Jabbari , Liza C. Villaruz , Mike Davis
artificial intelligence in medicine in europe 149 -159
2020
Crizotinib in Patients With MET-Amplified NSCLC
Umberto Conte , Yiyun Tang , Steven Ades , Geoffrey I. Shapiro
Journal of Thoracic Oncology 16 ( 6) 1017 -1029
43
2021
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
Ahmad A. Tarhini , Imran Rafique , Theofanis Floros , Phu Tran
Cancer 123 ( 15) 2936 -2944
39
2017
Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy
Jared M. Weiss , Nathan Pennell , Allison M. Deal , Daniel Morgensztern
Cancer 126 ( 5) 1060 -1067
3
2020
The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma
Liza C. Villaruz , Mark A. Socinski , Diana E. Cunningham , Simion I. Chiosea
Cancer 119 ( 12) 2268 -2274
63
2013
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium
Liza C. Villaruz , Mark A. Socinski , Shira Abberbock , Lynne D. Berry
Cancer 121 ( 3) 448 -456
112
2015
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Katerina Ancevski Hunter , Mark A. Socinski , Liza C. Villaruz
Molecular Diagnosis & Therapy 22 ( 1) 1 -10
64
2018
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon , Jeffrey W. Clark , Jared Weiss , Sai-Hong Ignatius Ou
Nature Medicine 26 ( 1) 47 -51
76
2020
MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
Liza C. Villaruz , Grace Huang , Marjorie Romkes , John M. Kirkwood
Clinical Epigenetics 7 ( 1) 58 -58
15
2015
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non‐Small Cell Lung Cancer and the Role of Biopsy at Progression
Mark A. Socinski , Liza C. Villaruz , Jeffrey Ross
Oncologist 22 ( 1) 3 -11
20
2017
ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Sanja Dacic , Liza C. Villaruz , Shira Abberbock , Alyssa Mahaffey
Oncotarget 7 ( 50) 82943 -82952
48
2016
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement
Liza C. Villaruz , Mark A. Socinski
Clinical Cancer Research 19 ( 10) 2629 -2636
58
2013
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes.
Liza C. Villaruz , Mark A. Socinski
European Journal of Cancer 56 162 -171
14
2016
RET rearrangements in lung adenocarcinoma and radiation.
Sanja Dacic , Alyssa Luvison , Viktoria Evdokimova , Lindsey Kelly
Journal of Thoracic Oncology 9 ( 1) 118 -120
17
2014
Alternative splicing of HER2: a novel mediator of EGFR TKI resistance.
Zachary A. Yochum , Liza C. Villaruz
Translational lung cancer research 9 ( 4) 1606 -1612
2020
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.
Matthew A. Gubens , Lecia V. Sequist , James P. Stevenson , Steven F. Powell
Lung Cancer 130 59 -66
21
2019
Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study
Shirish M. Gadgeel , James P. Stevenson , Corey J. Langer , Leena Gandhi
Lung Cancer 125 273 -281
66
2018
ATM protein is deficient in over 40% of lung adenocarcinomas
Liza C. Villaruz , Helen Jones , Sanja Dacic , Shira Abberbock
Oncotarget 7 ( 36) 57714 -57725
21
2016